Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. held its annual stockholder meeting on June 2, 2026. Stockholders elected Class II directors David Bourdon and Robert Bessler to three-year terms, with 244,968,319 and 280,015,618 votes cast for their elections, respectively.
Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ended December 31, 2026, with 357,756,707 votes for the proposal. In addition, stockholders approved, on a non-binding advisory basis, the company’s named executive officer compensation, with 322,904,359 votes in favor.
LifeStance Health Group, Inc. amendment to a Schedule 13G/A reports that TPG VIII Lynnwood (via TPG GP A, LLC and affiliated Reporting Persons James G. Coulter and Jon Winkelried) is associated with 111,744,614 shares of Common Stock, representing 29.3% of the class. The percentage is calculated based on 381,834,432 shares outstanding as of May 12, 2026, as cited from a Prospectus Supplement filed on May 8, 2026. The filing states shared voting and shared dispositive power over the reported shares and includes a joint filing agreement and related disclaimers of beneficial ownership to the extent of pecuniary interest.
LifeStance Health Group director Robert Bessler reported indirect open-market sales of company stock by entities associated with him. On May 12, 2026, Shama LLC and Vitthal LLC each sold 287,517 shares of LifeStance common stock at $8.02 per share, for a total of 575,034 shares.
After these transactions, Shama LLC held 1,103,729 shares and Vitthal LLC held 986,931 shares. Separate holding entries show 57,619 shares held directly by Bessler and 36,363 shares held indirectly. Footnotes state that Bessler disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
LifeStance Health Group director Eric Shuey reported an indirect share sale through a family trust. On this Form 4, the Eric Shuey Gift Trust completed an open-market sale of 243,362 shares of LifeStance common stock at a price of $8.02 per share. Following the transaction, the trust held 867,562 shares indirectly, while Shuey also reported 93,982 shares held directly. The filing notes that Shuey disclaims beneficial ownership of the trust-held securities except to the extent of his pecuniary interest.
LifeStance Health Group, Inc. director Darren M. Black reported an indirect open-market sale of 5,899,661 shares of Common Stock at $8.02 per share through Summit Partners–affiliated investment entities. After these transactions, the filing shows these entities holding 23,310,115 shares in total. The shares are held across several Summit funds, and the footnotes state that Summit Partners, L.P., via an investment committee that includes Black, has voting and dispositive power while each person and fund disclaims beneficial ownership except to the extent of pecuniary interest.
LifeStance Health Group, Inc. reported that an entity affiliated with TPG completed an open-market sale of 28,281,943 shares of Common Stock at $8.02 per share. After this transaction, TPG VIII Lynnwood Holdings Aggregation, L.P. continues to hold 111,744,614 shares indirectly, with the reporting persons only deemed beneficial owners to the extent of their pecuniary interests.
LifeStance Health Group, Inc. entered into an Underwriting Agreement with J.P. Morgan Securities LLC and certain selling stockholders for an underwritten offering of 35,000,000 shares of its common stock under an existing Form S-3 registration statement.
All 35,000,000 shares are being sold by the selling stockholders, so the Company did not receive any proceeds from the offering. Separately, the Company agreed to repurchase 6,000,000 of these shares from the Underwriter at the same price the Underwriter paid the selling stockholders, and the Underwriter received no compensation on the repurchased shares.
The offering closed on May 12, 2026. The filing also notes an opinion from Ropes & Gray LLP regarding the shares and lists the underwriting agreement and related legal opinion as exhibits.
LifeStance Health Group director Robert Bessler reported open-market sales of LifeStance Health Group, Inc. common stock through entities associated with him. Shama LLC and Vitthal LLC each sold 37,500 shares at a weighted average price of $8.55 per share, in transactions ranging from $8.40 to $8.89. After these sales, Shama LLC held 1,353,746 shares and Vitthal LLC held 1,236,948 shares. Bessler also reported 57,619 shares held directly and 36,363 shares held by Alpine Glow Capital. Footnotes state that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
Summit Partners and affiliated funds reported shared beneficial ownership of LifeStance Health Group common stock. Summit Partners, L.P. has 29,209,776 shares with shared voting and dispositive power, representing 7.49% of the class. The filing cites 389,783,210 shares outstanding as of February 17, 2026.
The Schedule 13G/A lists related Summit entities (including Growth Equity Fund IX‑A and IX‑B) with shared holdings of 17,886,858 and 11,168,308 shares respectively and explains the fund/committee voting structure and delegations.
LifeStance Health Group, Inc. is offering for resale 35,000,000 shares of common stock by selling stockholders; the Company is not selling any shares hereunder and will receive no proceeds from those sales. Subject to the closing of the offering, the Company intends to purchase 6,000,000 shares from the underwriter at the public offering price and retire them. The repurchase is contingent on the offering closing. Shares outstanding were 387,834,432 as of April 29, 2026. The underwriter is J.P. Morgan, the public offering price is $8.15 per share and the underwriting discount is $0.13 per share. The underwriter expects to deliver the shares on or about May 12, 2026.